VivoSeq
Nephrology

Acute Kidney Injury

150

Pipeline Programs↗

51

Active Trials↗

58

Companies Involved↗

Acute Kidney Injury is a highly competitive landscape with 150 programs across 58 companies. The most active players are Moderna, Boehringer Ingelheim, Sentien Biotechnologies, Inc.. 41 therapies are approved with 21 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

77/100

Pipeline Velocity

45/100

Mech. Concentration

10/100

Completion Rate

71/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Moderna logo

Moderna

1 program

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 1S

Sentien Biotechnologies, Inc.

1 program

Phase 2A

Aptabio Therapeutics, Inc.

1 program

Phase 2G

Guard Therapeutics AB

1 program

Phase 2H

Hope Biosciences LLC

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical46

Calcium Carbonate

Otsuka

Midodrine

Takeda

Polyethylene Glycol

Bayer

Ulinastatin

Techpool Bio-Pharma Co., Ltd.

Desvenlafaxine

Prism Pharmaceuticals

Phase 18

Mrna-3705

Moderna

Dexamethasone

Aspen Global Incorporated

Empagliflozin

Boehringer Ingelheim

Ibuprofen

Kenvue Brands

SGLT2 Inhibitor

Eli Lilly

Phase 234

Famotidine

Kenvue Brands

Pantoprazole

Wyeth-Lederle Vaccines

Febuxostat

Takeda

Vasopressin

Aultman Health Foundation

Droxidopa

Lundbeck

Phase 321

Epoetin Beta

Roche

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Spironolactone

Pfizer

Aminophylline

The Searle Company Limited Pakistan

Levosimendan

Orion Corporation, Orion Pharma

Approved41

Mannitol

B. Braun Medical Inc.

Furosemide

Validus Pharmaceuticals

Desflurane

Baxter Healthcare Corporation

Acetylcysteine

Arbor Pharmaceuticals, Inc.

Ambrisentan

Gilead

Analysis

Modality Breakdown

96%

Small molecule

163 of 170 classified programs — the dominant modality here.

4%ALL OTHERSCell therapy32%Monoclonal antibody1<1%Protein / enzyme1<1%Peptide1<1%RNA therapy1<1%

Small molecule leads; the ring shows all 170 classified programs, each share of the total. Modality classified for 100% of 179 pipeline programs.

Analysis

Trial Status

173

clinical trials

Completed61 · 35%
Unknown status36 · 21%
Recruiting29 · 17%
Terminated18 · 10%
Not yet recruiting15 · 9%
Active, not recruiting7 · 4%
Other7 · 4%

Clinical Trials

Trial Activity

173 trials

Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury
Recruiting·UUniversity of Michigan·Phase 2·NCT07016074·100 enrolled
Comparison of Early Caffeine Administration Vs Supportive Therapy in Preventing Acute Kidney Injury
Recruiting·—·N/A·NCT07305935·236 enrolled
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)
Recruiting·TThe University of Texas Health Science Center, Houston·Phase 2·NCT06706258·400 enrolled
Albumin To Enhance Recovery After Acute Kidney Injury
Recruiting·OOttawa Hospital Research Institute·Phase 4·NCT04705896·856 enrolled
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients
Recruiting·TThe University of Texas Health Science Center, Houston·Phase 2/3·NCT06531642·100 enrolled
PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care
Recruiting·TThe George Institute·Phase 3·NCT05468203·3,000 enrolled
LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery
Recruiting·AArch Biopartners Inc.·Phase 2·NCT05879432·240 enrolled
Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin
Recruiting·—·Phase 2·NCT06886464·698 enrolled
Hypertonic Saline Solution to Prevent Acute Kidney Injury After Heart Transplantation
Recruiting·—·Phase 2·NCT05909150·74 enrolled
The Effect of Preoperative Albumin Administration on Postoperative Acute Kidney Injury in Pediatric Patients With Hypoalbuminemia Undergoing Cardiac Surgery
Recruiting·SSeoul National University Hospital·N/A·NCT06710353·190 enrolled
Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06344442·304 enrolled
Use of Vasopressin in Patients at High Risk of Acute Kidney Injury Admitted to the ICU
Recruiting·HHospital do Coracao·Phase 2·NCT06547892·60 enrolled
Incidence of Acute Kidney Injury After Administration of Iodine Contrast Media in Patients With Reduced Renal Function
Recruiting·UUppsala University·N/A·NCT06171958·400 enrolled
Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI
Recruiting·AAptabio Therapeutics, Inc.·Phase 2·NCT05758896·280 enrolled
Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury
Recruiting·—·Phase 2·NCT06954740·50 enrolled
Page 1 of 12

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)